Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Edgewise Therapeutics (EWTX) Shares Outstanding (Weighted Average) (2020 - 2026)

Edgewise Therapeutics has reported Shares Outstanding (Weighted Average) over the past 7 years, most recently at $107.1 million for Q1 2026.

  • Quarterly results put Shares Outstanding (Weighted Average) at $107.1 million for Q1 2026, up 12.6% from a year ago — trailing twelve months through Mar 2026 was $107.1 million (up 12.6% YoY), and the annual figure for FY2025 was $102.9 million, up 11.38%.
  • Shares Outstanding (Weighted Average) reached $107.1 million in Q1 2026 per EWTX's latest filing, up from $102.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $107.1 million in Q1 2026 and bottomed at $49.5 million in Q1 2022.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $87.6 million (2024), compared with a mean of $78.8 million.
  • Peak annual rise in Shares Outstanding (Weighted Average) hit 3076.2% in 2022, while the deepest fall reached 0.74% in 2022.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $53.6 million in 2022, then rose by 18.9% to $63.7 million in 2023, then soared by 45.02% to $92.4 million in 2024, then rose by 11.38% to $102.9 million in 2025, then increased by 4.07% to $107.1 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for EWTX at $107.1 million in Q1 2026, $102.9 million in Q4 2025, and $105.5 million in Q3 2025.